Drugs / SPGL008
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07038005 | Jul 2025 → Sep 2026 overdue | cancer | Shenyang Sunshine Pharmaceutical Co., LTD. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07445308 | Mar 2026 → Nov 2028 expected | non-invasive bladder urothelial carcinoma | Shenyang Sunshine Pharmaceutical Co., LTD. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPGL008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07038005 ↗ |
| Route | Intravenous | “intravenous and subcutaneous administration” NCT07038005 ↗ |
| Route | Subcutaneous | “intravenous and subcutaneous administration” NCT07038005 ↗ |